accountMay 15 (Bloomberg) -- Biotechnology companies struggling with funding shortages because of the global credit crisis will be scrambling for the attention of cash-rich drugmakers at the world’s largest annual meeting of cancer doctors.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Biotech Sellers Dangle Data for Cash at Cancer Drug Bazaar
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account